38191-33-2

Basic information

• Product Name: 2-AMINO-6-CHLORO-PHENOL
• Synonyms: phenol, 2-amino-6-chloro-;2-chloro-6-aMinophenole;3-Chloro-2-hydroxyaniline;2-AMino-6-chlorphenol
• CAS NO: 38191-33-2
• Molecular Formula: C₆H₆ClNO
• Molecular Weight: 143.57
• Mol File: 38191-33-2.mol

Chemical Properties

• Melting Point: 80-81℃
• Boiling Point: 247℃
• Flash Point: 103℃
• Appearance: /
• Density: 1.406
• Vapor Pressure: 0.0163mmHg at 25°C
• Refractive Index: 1.65
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 8.28±0.10(Predicted)
• CAS DataBase Reference: 2-AMINO-6-CHLORO-PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-6-CHLORO-PHENOL(38191-33-2)
• EPA Substance Registry System: 2-AMINO-6-CHLORO-PHENOL(38191-33-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 38191-33-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-6-chloro-phenol is utilized as an intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs, particularly those with potential anti-cancer properties. Research is ongoing to explore its mechanisms of action and to determine its full potential as a therapeutic agent.
Used in Cosmetic Industry:
In the cosmetic industry, 2-amino-6-chloro-phenol is commonly used in the production of hair dyes. Its presence in these products can impart color to hair, but it is important to note that it may cause allergic reactions in some individuals. As a result, caution is advised when using hair dye products containing this chemical, and consumers should be aware of the potential risks associated with its use.
While the provided materials do not explicitly mention other industries where 2-amino-6-chloro-phenol might be used, its chemical properties suggest that it could have applications in other areas, such as chemical synthesis, material science, or as a research tool in various scientific fields. Further investigation and research would be necessary to identify and validate these potential uses.

InChI:InChI=1/C6H6ClNO/c7-4-2-1-3-5(8)6(4)9/h1-3,9H,8H2

Upstream product

• 3209-22-1 1,2-Dichloro-3-nitrobenzene 
• 95-57-8 2-monochlorophenol 
• 603-86-1 2-chloro-6-nitrophenol 
• 7439-89-6 iron 

Downstream Products

• 876-86-8 7-chloro-quinolin-8-ol 
• 51793-93-2 7-chlorobenzo[d]oxazole-2-thiol 
• 84326-06-7 [4-(8-Chloro-2-oxo-2H-benzo[1,4]oxazin-3-yl)-phenyl]-acetic acid methyl ester 
• 84326-12-5 2-[4-(8-Chloro-2-oxo-2H-benzo[1,4]oxazin-3-yl)-phenyl]-propionic acid methyl ester 
• 121996-73-4 diethyl N-(3-chloro-2-hydroxyphenyl)aminomethylenemalonate 
• 939759-05-4 8-chloro-3,4-dihydro-2Hbenzo[b][1,4]oxazine 
• 57245-31-5 8-chloro-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 89284-62-8 3-Chlor-benzochinon-(1,2)-diazido-⁽¹⁾ 
• 1228575-41-4 3-((3-chloro-2-hydroxyphenyl)amino)-4-ethoxycyclobut-3-ene-1,2-dione 
• 64037-11-2 7-chlorobenzo[d]oxazol-2-amine 
• 1345459-56-4 2-bromo-2,2-difluoro-N-(2-hydroxy-3-chlorophenyl)acetamide 
• 1319148-17-8 C₁₂H₁₃ClN₂O₄ 
• 1319147-98-2 C₁₁H₁₀ClN₅O₂S 
• 1319147-82-4 3-{5-[(E)-(3-chloro-2-hydroxyphenyl)diazenyl]-4-methyl-6-oxo-2-thioxo-5,6-dihydropyrimidin-1(2H)-yl}-2-(chloromethyl)quinazolin-4(3H)-one 

Relevant articles and documents

Direct Hydrogenation of Nitroaromatics at Room Temperature Catalyzed by Magnetically Recoverable Cu@Fe2O3 Nanoparticles

Metal embedded in metal oxide nanoparticles are active as catalyst in plethora of industrially important reactions. Herein, embedded Cu@Fe2O3 nanoparticles was synthesized via a one step hydrothermal strategy which selectively catalyzes the hydrogenation of diverse nitroaromatics in H2O at room temperature. The remarkable catalytic performance is due to the successful hybridization of metallic Cu and Fe2O3 which in turn allows easy electroflipping between various oxidation states of Cu and Fe. Azo- and azoxy-compounds are not formed during the catalyzed process. This evidently establish that the hydrogenation of nitroaromatics proceeds via direct route with >99percent selectivity to the corresponding anilines.

High catalytic activity of a new Ag phosphorus ylide complex supported on montmorillonite: synthesis, characterization, and application for room temperature nitro reduction

In this work, the phosphorus ylide, [PPh3CHC(O)CH2Cl], was reacted with AgNO3 to give the [Ag{C(H)PPh3C(O)CH2Cl}2]+NO3? as the product. Then, it was supported on the modified montmorillonite nanoclay to prepare a new catalyst for the reduction reaction. The structure and morphology of the nanoclay catalyst were characterized by FT-IR, X-ray powder diffraction, scanning electron microscopy, energy-dispersive X-ray analysis and transmission electron microscopy techniques; also, the content of silver was obtained by inductively coupled plasma analyzer. This composition was exploited to study its catalytic activity in the reduction in aromatic nitro compounds; it displayed the high catalytic activity. Factors such as catalyst amount, solvent, temperature and reaction time were all systematically investigated to elucidate their effects on the yield of catalytic reduction in nitroarenes. This catalytic system exhibited high activity toward aromatic nitro compounds under mild conditions. The catalyst was reused five times without any significant loss in its catalytic activity.

Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors

Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and pharmacologic evidence. Small molecules that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the molecules stabilize the native state over the dissociative transition state—thereby inhibiting amyloidogenesis. Herein, we use previously reported structure-activity relationship data to develop two semi-quantitative algorithms for identifying the structures of potent and selective transthyretin kinetic stabilizers/amyloidogenesis inhibitors. The viability of these prediction algorithms, in particular the more robust in silico docking model, is perhaps best validated by the clinical success of tafamidis, the first-in-class drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a fully-enrolled placebo-controlled clinical trial for its efficacy against TTR cardiomyopathy. These prediction algorithms will be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate the central nervous system or ophthalmologic pathology caused by TTR aggregation in organs not accessed by oral tafamidis administration.

Fe-Catalyzed Amination of (Hetero)Arenes with a Redox-Active Aminating Reagent under Mild Conditions

A novel and efficient Fe-catalyzed direct C?H amination (NH2) of arenes is reported using a new redox-active aminating reagent. The reaction is simple, and can be performed under air, mild, and redox-neutral conditions. This protocol has a broad substrate scope and could be used in the late-stage modification of bioactive compounds. Mechanistic studies demonstrate that a radical pathway could be involved in this transformation.

2-Aminobenzoxazole ligands of the hepatitis C virus internal ribosome entry site

2-Aminobenzoxazoles have been synthesized as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The compounds were designed to explore the less basic benzoxazole system as a replacement for the core scaffold in previously discovered benzimidazole viral translation inhibitors. Structure-activity relationships in the target binding of substituted benzoxazole ligands were investigated.

Difluoromethylbenzoxazole pyrimidine thioether derivatives: A novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors

This paper reports the synthesis and antiviral properties of new difluoromethylbenzoxazole (DFMB) pyrimidine thioether derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. By use of a combination of structural biology study and traditional medicinal chemistry, several members of this novel class were synthesized using a single electron transfer chain process (radical nucleophilic substitution, SRN1) and were found to be potent against wild-type HIV-1 reverse transcriptase, with low cytotoxicity but with moderate activity against drug-resistant strains. The most promising compound 24 showed a significant EC50 value close to 6.4 nM against HIV-1 IIIB, a moderate EC50 value close to 54 μM against an NNRTI resistant double mutant (K103N + Y181C), but an excellent selectivity index >15477 (CC50 > 100 μM).

Regulatory molecules for the 5-HT3 receptor ion channel gating system

Substituted benzoxazole derivatives which possess a nitrogen-containing heterocycle at C2 are selective partial agonists of the 5-HT3 receptor. Alteration of substituents on the benzoxazole nucleus affords both agonist-like and antagonist-like compounds, and uniquely modifies the function of the 5-HT3 receptor ion channel gating system. SAR and corroborative computational docking study for these partial agonists successfully explained structure and function of the 5-HT3 receptor.

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

Carboxylic Acid Compounds and Use Thereof

Provision of a superior URAT1 activity inhibitor effective for the treatment and the like of a pathology involving uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary lithiasis, renal dysfunction, coronary heart disease, ischemic cardiac diseases and the like. A URAT1 activity inhibitor containing a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient: [image] wherein each symbol is as defined in the specification.

Pyrazolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.